Fibronostics Acquires Stone Clinical Laboratories

October 27, 2025

Fibronostics has completed the acquisition of Stone Clinical Laboratories, LLC, expanding its U.S. laboratory infrastructure to accelerate innovation in non-invasive diagnostics for metabolic and liver diseases (MASH/MASLD). The deal strengthens Fibronostics' R&D and testing capabilities, combining Stone Clinical's laboratory expertise with Fibronostics' proprietary LIVERFASt platform to support biomarker development, clinical validation, and collaborations with biopharma and healthcare partners.

Buyers
Fibronostics
Targets
Stone Clinical Laboratories, LLC
Location
United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.